Wed, 14th Apr 2021 16:10
OTTAWA, April 14 (Reuters) - Canada's health ministry said
on Wednesday it would not restrict use of AstraZeneca PLC's
COVID-19 vaccine at this time after a review showed the
benefits outweighed the very rare risk of blood clots.
A separate advisory council had earlier recommended Canada
stop offering the vaccine to people under 55. The panel is now
reviewing that advice, the health ministry said in a statement.
(Reporting by David Ljunggren)
(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for pr...
(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood canc...
April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negoti...
(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:
(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while a...
Astrazeneca (AZN)